Mannkind Corp (MNKD) 9.77 $MNKD
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
MannKind Up 29.2% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 21, 4:53PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 29.18% as of today's recent price of $9.63.
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver
PR Newswire - Mon Jul 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, CVS, ESRX, LNG, and AWAY.
Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne
at The Street - Mon Jul 21, 8:19AM CDT
Here are some technical guidelines that you may be able to profit from.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
MannKind Up 35.1% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 14, 11:02AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.08% as of today's recent price of $10.07.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
5 Stocks to Watch This Week
Rick Munarriz, The Motley Fool - Motley Fool - Sat Jul 12, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday Peregrine Pharmaceuticals kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is...
SmarTrend Watching for Potential Pullback in Shares of MannKind After 1.82% Gain
Comtex SmarTrend(R) - Fri Jul 11, 5:24PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.81 to a high of $10.10. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $9.98 on volume of 5.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Is This MannKind's Greatest Risk?
Keith Speights, The Motley Fool - Motley Fool - Fri Jul 11, 4:00PM CDT
Not long ago, some predicted that MannKind faced the serious risk of striking out on winning approval for Afrezza. Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin. With...
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
MannKind Shares Up 35.3% Since SmarTrend's Buy Recommendation (MNKD)
Comtex SmarTrend(R) - Mon Jul 07, 9:37AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.35% as of today's recent price of $10.09.
3 Things to Look for in MannKind's Partnership
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 04, 4:00PM CDT
It's been a week since MannKind gained Food and Drug Administration approval for its inhaled insulin Afrezza, and the biotech still hasn't announced a marketing partner. What's taking so long? I jest. But I'm allowed to. MannKind has been...
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.
Most active Nasdaq-traded stocks
AP - Thu Jul 03, 4:15PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 03, 10:15AM CDT
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company's lead product - Afrezza inhalation powder - was recently approved by the FDA as a rapid-acting insulin therapy intended to improve glycemic control in adults with type 1 or type 2 diabetes. MannKind was founded by Al Mann for the purpose of developing inhaled insulin as an alternative to traditional injected insulin.
Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
George Budwell, The Motley Fool - Motley Fool - Thu Jul 03, 7:42AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Bind Therapeutics , MannKind Corp. and Shire . AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still...
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
MannKind Up 29.2% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 21, 4:53PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 29.18% as of today's recent price of $9.63.
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver
PR Newswire - Mon Jul 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, CVS, ESRX, LNG, and AWAY.
Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne
at The Street - Mon Jul 21, 8:19AM CDT
Here are some technical guidelines that you may be able to profit from.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
MannKind Up 35.1% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 14, 11:02AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.08% as of today's recent price of $10.07.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
5 Stocks to Watch This Week
Rick Munarriz, The Motley Fool - Motley Fool - Sat Jul 12, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday Peregrine Pharmaceuticals kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is...
SmarTrend Watching for Potential Pullback in Shares of MannKind After 1.82% Gain
Comtex SmarTrend(R) - Fri Jul 11, 5:24PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.81 to a high of $10.10. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $9.98 on volume of 5.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Is This MannKind's Greatest Risk?
Keith Speights, The Motley Fool - Motley Fool - Fri Jul 11, 4:00PM CDT
Not long ago, some predicted that MannKind faced the serious risk of striking out on winning approval for Afrezza. Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin. With...
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
MannKind Shares Up 35.3% Since SmarTrend's Buy Recommendation (MNKD)
Comtex SmarTrend(R) - Mon Jul 07, 9:37AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.35% as of today's recent price of $10.09.
3 Things to Look for in MannKind's Partnership
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 04, 4:00PM CDT
It's been a week since MannKind gained Food and Drug Administration approval for its inhaled insulin Afrezza, and the biotech still hasn't announced a marketing partner. What's taking so long? I jest. But I'm allowed to. MannKind has been...
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.
Most active Nasdaq-traded stocks
AP - Thu Jul 03, 4:15PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 03, 10:15AM CDT
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company's lead product - Afrezza inhalation powder - was recently approved by the FDA as a rapid-acting insulin therapy intended to improve glycemic control in adults with type 1 or type 2 diabetes. MannKind was founded by Al Mann for the purpose of developing inhaled insulin as an alternative to traditional injected insulin.
Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
George Budwell, The Motley Fool - Motley Fool - Thu Jul 03, 7:42AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Bind Therapeutics , MannKind Corp. and Shire . AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still...
